Myriad’s $210 Million Prenatal Exit Gives Labcorp a Larger Genetic Testing Footprint
Myriad Genetics agreed to sell its prenatal health testing business to Labcorp for $210 million, streamlining one portfolio while expanding the other.
Ultragenyx Shares Sink More Than 40% After Apazunersen Fails Phase 3 Trial
Ultragenyx shares fell more than 40% after apazunersen failed both Phase 3 endpoints, spotlighting b…
Rare-Disease Biotech Stocks Gain Focus After Protagonist’s $275 Million Milestone and Agios Phase 3 Data
A $275 million Protagonist milestone and Agios’ mixed Phase 3 RISE UP data put rare blood-disease ca…
Novo Nordisk’s CagriSema Delivers 25% Weight Loss in Women as GLP-1 Race Intensifies
CagriSema’s 25% weight-loss result could strengthen Novo Nordisk’s growth narrative as competition w…
Oracle’s Rising Credit Risk Puts the AI Infrastructure Boom to the Test
Oracle’s rising CDS costs offer a warning signal for debt-financed AI infrastructure—and a test of w…
Disc Medicine’s Bitopertin Data Revive FDA Hopes as IRON Stock Surges
Disc Medicine’s bitopertin data delivered a 41.4% biomarker reduction and more pain-free hours, revi…
Centrus Energy’s $116 Million Westerman Deal Puts Domestic Centrifuge Capacity in Focus
Centrus Energy’s planned $116 million acquisition of Westerman could deepen its domestic centrifuge …
TriGemX Bio Plans $600 Million SPAC Merger With TCGX
TriGemX Bio plans to enter public markets through a $600 million merger with TCGX, adding a new biot…
Disc Medicine Stock Jumps 70% After Positive Phase 3 Bitopertin Results
Disc Medicine’s $IRON surged more than 70% after positive Phase 3 data for bitopertin, putting a pot…
CoreWeave Credit Stress Deepens as AI Sell-Off Pushes Volatility Higher
CoreWeave’s rising bond yields and credit-default swaps are flashing caution as AI and chip stocks s…